Maverix Biomics and Diagnomics have received CLIA validation for their pre-natal molecular diagnostic on a next-generation sequencing platform.
Prices in Germany for noninvasive prenatal testing have plummeted over the last year, driven by competition and process improvements.
Under the agreement, OriGen will send maternal blood samples to Premaitha's clinical laboratory in the UK, which will analyze them using the firm's Iona test.
The study, published online in Prenatal Diagnosis last month, analyzed 40 websites from noninvasive prenatal test providers in detail.
The initiative aims to educate patients and healthcare providers about the benefits and limitations of NIPT screening and how to interpret the results.
Recent cost analyses funded by Ariosa and Natera found that NIPT could replace conventional screening in the US and be cost-neutral if provided at certain prices.
The researchers identified a large set of potential markers, and then narrowed them down to those with the most practical diagnostic potential.
Chromsomal array testing had a higher diagnostic yield in the study than standard procedures, and could have value as a first step before referring patients to further tests.
The change makes Anthem one of the first major payors to say that NIPT is medically necessary for the non-high-risk pregnancy population.
The Center for Human Genetics and Laboratory Medicine's Prenatalis test is based on Illumina's Verifi technology.
The Wall Street Journal looks into FamilyTreeDNA's handling of genetic genealogy searches by law enforcement.
In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.
MIT's Technology Review reports that researchers hope to develop a CRISPR-based pain therapy.
In Science this week: atlas of malaria parasites' gene expression across their life cycles, and more.